Product image of Neisvac-C1 (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A) supplied by GNH India

Neisvac-C1

Active Ingredient:
N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A
Origin:
EU

Neisvac-C1 (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A)

N. meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid A, the active ingredient in Neisvac-C1, is a conjugate vaccine presented as a sterile powder for intramuscular use. It induces immunity against invasive disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents and adults.

GNH India supplies Neisvac-C1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratórios Pfizer Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neisvac-C1 is a conjugate vaccine targeting the meningococcal disease pathway caused by Neisseria meningitidis serogroup C.

  • Infants and young children: provides active immunity against serogroup C meningococcal disease.
  • Adolescents and adults: maintains protective antibody levels to prevent invasive disease.
  • Travelers to endemic regions: reduces risk of acquiring Neisseria meningitidis serogroup C infection.

How It Works

  • Neisvac-C1 contains a de‑O‑acetylated capsular polysaccharide of N. meningitidis group C covalently linked to tetanus toxoid. The conjugate enables a T‑cell‑dependent immune response, prompting B‑cells to produce high‑affinity IgG antibodies that specifically recognize the polysaccharide capsule, thereby neutralising the bacteria and providing long‑lasting protection against invasive meningococcal disease.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the site of administration.
  • Redness or swelling: localized erythema or edema that resolves within a few days.
  • Fever: transient low‑grade temperature elevation.
  • Headache or fatigue: mild systemic symptoms post‑vaccination.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with muscle weakness.
  • Seizures: uncommon occurrence, especially in febrile children.
  • Severe local reaction: extensive necrosis or abscess formation at injection site.
  • Immune‑mediated thrombocytopenia: rare drop in platelet count.

Precautions & Warnings

Precautions should be observed when administering Neisvac-C1.

  • Pregnancy: safety not established; vaccinate only if clearly needed.
  • Breastfeeding: consider risk‑benefit balance before use.
  • Immunocompromised patients: may exhibit reduced antibody response.
  • History of severe allergic reaction to tetanus toxoid or any vaccine component: avoid administration.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential interactions with other medicines or vaccines are limited.

Major Interactions (Avoid)

  • Severe allergic reaction to tetanus toxoid: contraindicates use of Neisvac-C1.
  • Simultaneous injection of another vaccine containing tetanus toxoid at the same site: may increase risk of local adverse reactions.

Moderate Interactions (Monitor Closely)

  • Concurrent administration of immunoglobulins: may diminish vaccine efficacy.
  • Use of immunosuppressive therapy: may reduce immune response to the vaccine.

Frequently Asked Questions

Neisvac-C1 is a conjugate vaccine indicated for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is administered to individuals at risk, including infants, children, adolescents, adults, and travelers to regions where serogroup C meningococcal disease is endemic.

The vaccine contains a de‑O‑acetylated polysaccharide from the capsular coat of N. meningitidis group C linked to tetanus toxoid. This conjugation creates a T‑cell‑dependent antigen that stimulates robust IgG antibody production, enabling the immune system to recognize and neutralise the bacteria upon exposure.

The dosing schedule for Neisvac-C1 is determined by the prescribing healthcare professional based on the patient’s age, health status, and vaccination history. The prescriber will decide the number of doses, interval between doses, and any booster requirements.

Safety data for Neisvac-C1 in pregnancy are limited, so it should only be given when the potential benefit outweighs any potential risk. Breastfeeding is not a contraindication, but the decision should be made after evaluating the risk‑benefit profile for mother and infant.

To order Neisvac-C1, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, cold‑chain shipping details and import documentation.

Neisvac-C1 is a polysaccharide‑tetanus toxoid conjugate vaccine targeting serogroup C, offering a T‑cell‑dependent response and longer‑lasting immunity compared with plain polysaccharide vaccines. It differs from quadrivalent conjugate vaccines that also cover serogroups A, W, and Y, focusing solely on serogroup C protection.

Neisvac-C1 must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If a temporary temperature excursion occurs, consult the product’s stability guidelines before use.

Neisvac-C1 is administered by a single intramuscular injection, typically into the deltoid muscle of the upper arm. The exact site and technique are determined by the healthcare professional performing the vaccination.

The most serious adverse events associated with Neisvac-C1 include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and rare neurological complications like seizures. Immediate medical attention is required if any signs of a serious reaction appear after vaccination.

Individuals with a known severe allergy to tetanus toxoid or any component of the vaccine should not receive Neisvac-C1. Additionally, those who have experienced a serious adverse reaction to a previous dose of a meningococcal conjugate vaccine should avoid further administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT